Organization
NOXXON Pharma AG
Topic
All Topics
People
Find news about people
Alumni
Find news on alumni of any org
Industries
Find news on a particular market
Your Contacts
Find news on your contacts
Sign up for free daily alerts on this feed:
By pressing Sign Up, you agree to our Terms of Use, Privacy Policy, and the LexisNexis Terms & Conditions

Follow

Change Feed
NOXXON Pharma AG
... NOXXON Pharma Announces Collaboration with National Center for Tumor Diseases in Heidelberg For ...
... as Chief Medical Officer and member of the Executive Board of NOXXON Pharma AG, a Berlin-based biotech company that focuses on cancer therapies, where he ...
... H2 2016 - Key Players Are Astellas Pharma Inc, Nekonal Sarl, Noxxon Pharma AG & Pelican Therapeutics - Research and Markets ...
... - Otsuka Pharmaceutical - Opko Health - Portola Pharmaceuticals Inc. - Noxxon Pharma Ag - Momenta Pharmaceuticals - Medkoo Biosciences - The Medicines Co. - ...
... Nordic Bioscience A/S, Novartis AG, NovaTarg Therapeutics, Inc, Novo Nordisk A/S, Noxxon Pharma AG, Omeros Corporation, OPKO Health, Inc., Oramed Pharmaceuticals, Inc., Orbis Biosciences, Inc., ...
... Corporation, Nexgenix Pharmaceuticals, LLC, Northwest Biotherapeutics, Inc., Novartis AG, Novogen Limited, Noxxon Pharma AG, Omniox, Inc., Oncobiologics, Inc., Oncodesign SA, Oncolytics Biotech Inc., Onconova Therapeutics, ...
... Michele & Stephen Kirsch Laboratory. Aram Mangasarian, PhD, Chief Executive Officer of NOXXON Pharma, commented: "There is an increasing body of evidence which points towards ...
... Johnson, Mallinckrodt plc, Mesoblast Limited, Mitsubishi Tanabe Pharma Corporation, NephroGenex, Inc., Noxxon Pharma AG, Omeros Corporation, OncoImmune, Inc., Otsuka Holdings Co., Ltd., Pfizer Inc., PhytoHealth ...
... NOXXON Spiegelmer® Receives FDA Orphan Drug Designation for Glioblastoma Treatment NOXXON Spiegelmer® Receives FDA Orphan Drug Designation for Glioblastoma Treatment NOXXON Pharma announced ...
... Study Selected for Late Breaking Clinical Trials Symposium during ERA-EDTA Conference . NOXXON's Emapticap Pegol Study Selected for Late Breaking Clinical Trials Symposium during ERA-EDTA ...
... -- Mesoblast Ltd. -- NephroGenex Inc. -- Novo Nordisk A/S -- NOXXON Pharma AG -- OncoImmune Inc. -- Pfizer Inc. -- PhytoHealth Corp. -- Questcor ...
... Increases Hemoglobin in Subset of Anemic Patients in Pilot Phase IIa Study NOXXON Pharma announced that data from a PhaseIIa pilot study in anemic cancer ...
... Presents Positive Results from Emapticap Pegol Phase IIa Diabetic Nephropathy Study . NOXXON Presents Positive Results from Emapticap Pegol Phase IIa Diabetic Nephropathy Study NOXXON ...
... IIa Results for Spiegelmer® Olaptesed Pegol (NOX-A12) in CLL and MM Studies NOXXON Pharma disclosed interim data from two independent clinical phase IIa studies of ...
... NOXXON Pharma today announced the successful completion of patient recruitment of its NOX-E36 ...
Want to see the full history of news or view news on a particular date? Upgrade to RelSci Professional now!
Start My Free Trial ➤